Patent ID: 11931334
Assignee: PLEOPHARMA, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 16:
17. The method of claim 1, wherein the treatment results in a reduction in cannabis withdrawal syndrome symptoms as measured by one or more assessment tool selected from the group consisting of WBS score, WBS 6 question subscale score, CWS 6 question subscale score, the Craving subscale, PGI-S scale, PGI bothersomeness scale or CGI scale, wherein the daily dose of nabilone and gabapentin is adjusted in a manner that maintains a withdrawal score on the selected assessment tool as selective from the group consisting of, a score of 40 or less on the CWS, a score of 25 or less on the CWS 6 question subscale, a score of 20 or less on the WBS, a score of 4 or less on WBS 6 question subscale, a score of 2 or less on the Craving subscale, a score of 1.5 or less on the PGI-S scale, a score of 1.0 or less on the PGI bothersomeness scale or a score of 1.5 or less on the CGI.